Understand AI for medical devices, FDA status, device support workflows, cybersecurity, intended use, and post-market monitoring.
Representative source image: official LumineticsCore product page.
Quick answer: AI for medical devices can be part of regulated software, imaging systems, monitoring devices, decision support, or support operations. Buyers and manufacturers should verify intended use, FDA status, cybersecurity, monitoring, and update controls.
Who this guide is for
Device manufacturers, providers, health systems, and support teams.
What makes this workflow different
Device-related AI requires intended-use discipline, cybersecurity review, and update monitoring.
What to verify before using it
Confirm whether the AI function is a medical device function.
Verify FDA records when device claims are made.
Document software updates and model-change policy.
Review cybersecurity and incident response.
Keep customer support language aligned with approved intended use.
Risk level and safe use
Medical risk
High
Best first step
Write the workflow in one sentence, decide who reviews the AI output, and test with a small controlled pilot before expanding.
Recommended posture
Use AI as supervised workflow support. Verify sources, privacy, human review, and regulatory fit before relying on outputs.
Source-backed products for this workflow
These profiles are not rankings. They are starting points for checking vendor claims, privacy terms, FDA or regulatory posture, evidence, and workflow fit.
Cognoa describes Canvas Dx as an FDA-authorized AI and machine-learning diagnostic system for diagnosing or ruling out autism in children ages 1.5 to 6 years; FDA's De Novo record for DEN200069 classifies the Cognoa ASD Diagnosis Aid as a pediatric autism spectrum disorder diagnosis aid, and Cognoa's indications state it is prescription-only, adjunctive, and intended for trained healthcare professionals using patient history, clinical observations, and other evidence.
Best for
Organizations trying to shorten autism evaluation wait times while keeping diagnosis, eligibility screening, result interpretation, family communication, and next-step care planning under qualified clinician control.
First check
FDA De Novo DEN200069, prescription-only status, indications for use, age range, caregiver language and smartphone requirements, exclusions, and whether any later cleared version is being deployed.
Avenda describes Unfold AI as FDA-cleared AI decision-support software that uses standard-of-care prostate MRI, fusion biopsy, pathology, and PSA data to generate a 3D cancer estimation map; FDA 510(k) K221624 covers Avenda Health AI Prostate Cancer Planning Software, and Avenda materials describe U.S. provider availability plus Category III code and CMS payment milestones.
Best for
Prostate cancer teams evaluating a regulated, physician-reviewed mapping input for focal therapy suitability, biopsy planning, ablation planning, or shared treatment decisions.
First check
FDA 510(k) K221624, current labeling, indications for use, trained-user requirements, and whether the evaluated product version is Unfold AI or an older iQuest-branded release.
icometrix describes icobrain as validated, FDA-cleared brain MRI AI software for comparing and quantifying neurological scans over time, with disease-specific reports across MS, dementia and Alzheimer's, ARIA, traumatic brain injury, epilepsy, Parkinson's disease, and brain tumors; FDA records list multiple icobrain 510(k) clearances for radiological image-processing software, while icobridge materials describe DICOM pseudonymization, TLS transfer, HIPAA/GDPR handling, and ISO27001 certification.
Best for
Programs that need standardized quantitative brain MRI reports for multiple sclerosis, dementia, ARIA, traumatic brain injury, epilepsy, Parkinson's disease, or brain tumor follow-up with specialist review.
First check
Which icobrain module is in scope: MS, dementia and Alzheimer's, ARIA, traumatic brain injury, epilepsy, Parkinson's disease, brain tumor, or another disease-specific report.
Artera describes ArteraAI Prostate as a multimodal AI test using digital pathology images and clinical data to estimate long-term outcomes and therapy benefit; official clinician materials cite NCCN guideline positioning, FDA documentation covers De Novo DEN240068 for ArteraAI Prostate, and partner materials describe a Tempus-integrated mHSPC clinical launch.
Best for
Prostate cancer programs that need an FDA-authorized, clinician-ordered AI risk-stratification input tied to pathology images, clinical data, and guideline-aware decision workflows.
First check
Whether the patient population matches the localized, non-metastatic, post-radical-prostatectomy, or metastatic hormone-sensitive prostate workflow being considered.
Sources
5 official sources
Official source trail for this workflow
Open these vendor, documentation, privacy, or regulatory sources before relying on product claims, especially for FDA status, PHI handling, deployment model, and intended use.
Find the best AI for medical workflows by matching the tool to documentation, questions, diagnosis support, research, coding, billing, imaging, or practice operations.
Understand AI for medical diagnosis, including validation evidence, FDA status, clinical supervision, and why patient-specific diagnosis should not rely on general chatbots.
